Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > LOL

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Oct 14, 2021 8:54pm

187 Views

Post# 34007607

RE:RE:RE:LOL

It’s looking pretty sus that you’re commenting now mugsy.

What’s your take on all this?

MrMugsy wrote:

SouthernTierTom wrote: When there is a program in place, the IDs are all interchangable. Chances are strong you are Mugs

Even the naive recognize these bullboard dramas

Hey - that's not fair ... I don't want to be associated with him.

: )